Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes
- Anne L. Peters, MD
Abstract
IN BRIEF
Patients with type 2 diabetes have high rates of cardiovascular disease (CVD), much of which may be preventable with appropriate treatment of lipid abnormalities. Diabetic dyslipidemia most commonly manifests as elevated triglycerides and low levels of HDL cholesterol, with a predominance of small, dense LDL particles amid relatively normal LDL cholesterol levels. In diabetic patients, non-HDL cholesterol may be a stronger predictor of CVD than LDL cholesterol or triglycerides because it correlates highly with atherogenic lipoproteins. Target goals for LDL and non-HDL cholesterol in patients with diabetes are < 100 and < 130 mg/dl, respectively. Failure to consider the importance of non-HDL cholesterol in type 2 diabetes may result in undertreatment of patients with diabetes.
Footnotes
-
Anne L. Peters, MD, is director of the University of Southern California Clinical Diabetes Program in Los Angeles.
-
Note of disclosure: Dr. Peters has received honoraria or consulting fees from AstraZeneca and Takeda. Both companies manufacture pharmaceutical products that affect cholesterol levels.
- American Diabetes Association
